CL2013000101A1 - Anticuerpo cd37 para tratar tumor maligno de celulas b; composicion farmacéutica que lo comprende. - Google Patents

Anticuerpo cd37 para tratar tumor maligno de celulas b; composicion farmacéutica que lo comprende.

Info

Publication number
CL2013000101A1
CL2013000101A1 CL2013000101A CL2013000101A CL2013000101A1 CL 2013000101 A1 CL2013000101 A1 CL 2013000101A1 CL 2013000101 A CL2013000101 A CL 2013000101A CL 2013000101 A CL2013000101 A CL 2013000101A CL 2013000101 A1 CL2013000101 A1 CL 2013000101A1
Authority
CL
Chile
Prior art keywords
understands
antibody
cells
pharmaceutical composition
malignant tumor
Prior art date
Application number
CL2013000101A
Other languages
English (en)
Spanish (es)
Inventor
Stephan Stilgenbauer
Thorsten Zenz
Karl-Heinz Heider
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44546328&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013000101(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2013000101A1 publication Critical patent/CL2013000101A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CL2013000101A 2010-07-16 2013-01-10 Anticuerpo cd37 para tratar tumor maligno de celulas b; composicion farmacéutica que lo comprende. CL2013000101A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10169795 2010-07-16
EP10175586 2010-09-07

Publications (1)

Publication Number Publication Date
CL2013000101A1 true CL2013000101A1 (es) 2013-12-27

Family

ID=44546328

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000101A CL2013000101A1 (es) 2010-07-16 2013-01-10 Anticuerpo cd37 para tratar tumor maligno de celulas b; composicion farmacéutica que lo comprende.

Country Status (15)

Country Link
US (3) US20120189618A1 (https=)
EP (2) EP2593479A1 (https=)
JP (2) JP2013538790A (https=)
KR (1) KR20130100918A (https=)
CN (2) CN103003309A (https=)
AU (1) AU2011278227B2 (https=)
BR (1) BR112013001012A2 (https=)
CA (1) CA2799036A1 (https=)
CL (1) CL2013000101A1 (https=)
EA (1) EA025365B1 (https=)
IL (1) IL222775A (https=)
MX (1) MX341463B (https=)
NZ (2) NZ703225A (https=)
PH (1) PH12013500118A1 (https=)
WO (1) WO2012007576A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20140196A1 (es) 2007-08-09 2014-03-19 Boehringer Ingelheim Int Anticuerpos anti-cd37
WO2013160396A1 (en) * 2012-04-26 2013-10-31 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with bendamustine
JP2015517511A (ja) 2012-05-16 2015-06-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３７抗体とｉｃｅ（イフォスファミド、カルボプラチン、エトポシド）の併用
US10294304B2 (en) 2015-04-13 2019-05-21 Pfizer Inc. Chimeric antigen receptors targeting B-cell maturation antigen
US11578115B2 (en) 2017-01-10 2023-02-14 The General Hospital Corporation Chimeric antigen receptors based on alternative signal 1 domains
CN118599009A (zh) 2017-03-16 2024-09-06 综合医院公司 靶向cd37的嵌合抗原受体
JP7330942B2 (ja) 2017-03-31 2023-08-22 ジェンマブ ホールディング ビー．ブイ． 二重特異性抗ｃｄ３７抗体、モノクローナル抗ｃｄ３７抗体、およびそれらの使用方法
WO2019243636A1 (en) 2018-06-22 2019-12-26 Genmab Holding B.V. Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof
EP3860715A1 (en) 2018-10-04 2021-08-11 Genmab Holding B.V. Pharmaceutical compositions comprising bispecific anti-cd37 antibodies
WO2023057595A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1 rew
WO2023057583A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1
AU2024362226A1 (en) 2023-10-18 2026-03-05 Debiopharm International S.A. Drug combination comprising anti-cd37 antibody maytansine conjugate and bcl2 inhibitor or pi3k inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
RU2423381C2 (ru) * 2005-07-25 2011-07-10 Трабьон Фармасьютикалз, Инк. Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул
US20080279850A1 (en) * 2005-07-25 2008-11-13 Trubion Pharmaceuticals, Inc. B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
JP2010532764A (ja) * 2007-07-06 2010-10-14 トゥルビオン・ファーマシューティカルズ・インコーポレーテッド Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド
PE20140196A1 (es) * 2007-08-09 2014-03-19 Boehringer Ingelheim Int Anticuerpos anti-cd37
RU2531754C2 (ru) * 2008-04-11 2014-10-27 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством
WO2010057047A1 (en) * 2008-11-13 2010-05-20 Trubion Pharmaceutics, Inc. Cd37 immunotherapeutic combination therapies and uses thereof

Also Published As

Publication number Publication date
EP3252077A1 (en) 2017-12-06
WO2012007576A1 (en) 2012-01-19
IL222775A (en) 2017-10-31
JP2017019800A (ja) 2017-01-26
US20120189618A1 (en) 2012-07-26
US20150266967A1 (en) 2015-09-24
CN105749276A (zh) 2016-07-13
MX2012013613A (es) 2012-12-17
NZ603161A (en) 2015-02-27
MX341463B (es) 2016-08-22
AU2011278227B2 (en) 2017-03-02
EA201201660A1 (ru) 2013-07-30
PH12013500118A1 (en) 2013-03-11
US20130236454A1 (en) 2013-09-12
CA2799036A1 (en) 2012-01-19
JP2013538790A (ja) 2013-10-17
EA025365B1 (ru) 2016-12-30
NZ703225A (en) 2016-11-25
BR112013001012A2 (pt) 2016-05-24
IL222775A0 (en) 2012-12-31
CN103003309A (zh) 2013-03-27
KR20130100918A (ko) 2013-09-12
AU2011278227A1 (en) 2012-11-15
EP2593479A1 (en) 2013-05-22

Similar Documents

Publication Publication Date Title
CL2013000101A1 (es) Anticuerpo cd37 para tratar tumor maligno de celulas b; composicion farmacéutica que lo comprende.
IL289300A (en) Combination therapy for treating cancer
CL2014002750A1 (es) Anticuerpo aislado o fragmento que se enlaza a un estado inactiva de un receptor her; composición farmacéutica que lo comprende; uso del anticuerpo para tratar cancer
IL262073B (en) Antibody drug conjugates (adc) that bind to 191p4d12 proteins
PT3214091T (pt) Utilização de células t modificadas por recetor de antigénio quimérico para tratar o cancro
KR102104197B9 (ko) 난소암의 치료를 위한 항혈관신생 요법
PT2694106T (pt) Métodos para aumentar eficácia de terapia de cancro de folr1
IL251083B (en) Compounds and compositions for the treatment of cancer
WO2013114367A8 (en) C10rf32 antibodies, and uses thereof for treatment of cancer
BR112014027477A2 (pt) métodos de processamento de materiais lingnocelulósicos.
PT2829881T (pt) Diagnóstico para cancro colo-rectal
WO2013123152A3 (en) ANTIBODIES TO INTEGRIN αVβ6 AND USE OF SAME TO TREAT CANCER
DK2818482T3 (da) Farmaceutisk sammensætning til behandling af cancer
DK2824114T3 (da) Farmaceutisk sammensætning til behandling af cancer
PL2598531T3 (pl) Sposoby i kompozycje do terapii nowotworu wątroby
IL224370B (en) Combination treatment for prostate carcinoma
HUE048876T2 (hu) Rákos megbetegedések kezelése
PL2739153T3 (pl) Leczenie raka sutka
BR112014028424A2 (pt) compostos de pirimidina para o tratamento de câncer
IL235585B (en) Ha binding agents, compositions comprising same and uses thereof
FR2955770B1 (fr) Composition cosmetique.
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
PT2931313T (pt) Formulações de solução de anticorpos anti-il-23p19 modificados
CL2014002951A1 (es) (r)-nifuratel; formulacion farmaceutica que lo contiene; y proceso para fabricar (r)-nifuratel y (s)-nifuratel.
BR112013015964A2 (pt) aperfeiçoamento para reatores mecano-químicos.